CG Oncology, Inc. (CGON): Total Liabilities
$38.99M
As of 2025-12-31
$56.54M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $38.99M | +82.0% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $21.42M | +47.6% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $14.51M | n/a | 2025-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | 2025-12-31 | $38.99M | +82.0% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $55.68M | +5.4% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $221.87M | +53.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $343.43M | +10.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $2.95M | -10.5% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $34.99M | -64.7% |
Compare CGON, OCGN, PRME, CRSP side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗